½ÃÀ庸°í¼­
»óǰÄÚµå
1570722

¼¼°èÀÇ ¼ºÀÎ¿ë ¹é½Å ½ÃÀå : ¹é½Å À¯Çüº°, ÀûÀÀ Áúȯº°, ÃÖÁ¾ »ç¿ëÀÚº° - ¿¹Ãø(2025-2030³â)

Adult Vaccines Market by Vaccine Type (Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines), Disease Indication (Hepatitis B, Herpes Zoster, Human Papillomavirus (HPV)), End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 182 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼ºÀÎ¿ë ¹é½Å ½ÃÀåÀÇ 2023³â ½ÃÀå ±Ô¸ð´Â 176¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 191¾ï 1,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, CAGR 8.28%·Î ¼ºÀåÇÒ Àü¸ÁÀ̰í, 2030³â¿¡´Â 307¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼ºÀÎ¿ë ¹é½Å ½ÃÀå¿¡´Â ¼ºÀÎ °¨¿° ¿¹¹æÀ» ¸ñÀûÀ¸·Î ÇÑ ¹é½Å ½ÃÀå °³Ã´, »ý»ê ¹× ¿ëµµ°¡ Æ÷ÇԵ˴ϴÙ. ÀÌ ½ÃÀåÀº ¼¼°è Àα¸ÀÇ °í·ÉÈ­, ¿¹¹æ °¡´ÉÇÑ Áúº´¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡, Á¤ºÎÀÇ ¿¹¹æ Á¢Á¾ ³ë·Â µîÀÇ ¿äÀο¡ ÀÇÇØ ¹é½Å Á¢Á¾ÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖÀ½¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. Àû¿ë ¹üÀ§¿¡´Â ÀÎÇ÷翣ÀÚ, ¼ö¸·¿°, HPV ¹× °£¿°¿¡ ´ëÇÑ ¹é½ÅÀÌ Æ÷ÇԵǸç ÃÖÁ¾ ¿ëµµ´Â °³ÀÎÀÇ °Ç°­ À¯Áö¿¡¼­ °øÁß º¸°Ç ÇÁ·Î±×·¥¿¡ À̸£±â±îÁö ´Ù¾çÇÕ´Ï´Ù. ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ÀÇ·á Á¤Ã¥¿¡ ´ëÇÑ Á¤ºÎÀÇ °ü½É Áõ°¡, ¹é½Å ±â¼úÀÇ Áøº¸, Áúº´ ¿¹¹æ¿¡ ´ëÇÑ ±¹¹ÎÀÇ ÀÇ½Ä Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. ¹é½Å Á¢Á¾·üÀÌ ³·Àº ½ÅÈï ½ÃÀå¿¡´Â ¼ºÀå ±âȸ°¡ ¸¹¾Æ ÀÇ·á¿¡ ´ëÇÑ ¾×¼¼½º Çâ»óÀÌ ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µË´Ï´Ù. ¾÷°è °¢ ȸ»ç´Â ¾Æ¿ô¸®Ä¡¿Í ±³À°À» È®´ëÇϱâ À§ÇØ ÀÇ·á Á¦°ø¾÷ü ¹× °øÁß º¸°Ç ±â°ü°úÀÇ Çù·Â¿¡ ÁÖ·ÂÇØ¾ß ÇÕ´Ï´Ù. ±×·¯³ª ¹é½Å Á¢Á¾ÀÇ ÁÖÀú, ±ÔÁ¦ Àå¾Ö¹°, À¯Åë ¹°·ù µîÀÇ °úÁ¦´Â ½ÃÀå È®´ë¸¦ Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ³ôÀº ¿¬±¸°³¹ß ºñ¿ë°ú ½Ã°£ÀÌ ¸¹ÀÌ °É¸®´Â ½ÂÀÎ ÇÁ·Î¼¼½º°¡ Å« °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. À̵éÀ» ±Øº¹Çϱâ À§Çؼ­´Â ¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê´Â ½Ã½ºÅÛ µîÀÇ Çõ½ÅÀûÀÎ Àü´Þ ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ³ª È¥ÇÕ ¹é½ÅÀÇ ¿¬±¸°¡ ÀáÀçÀûÀÎ ¼ºÀå ¼ö´ÜÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °³º° ¸é¿ª°èÀÇ º¯È­¿¡ ´ëÀÀÇÏ´Â °³ÀÎÈ­ ¹é½ÅÀº ½ÃÀå¿¡ Çõ¸íÀ» ÀÏÀ¸Å³ ¼ö ÀÖ½À´Ï´Ù. ¼ºÀÎ ¹é½Å ½ÃÀåÀÇ º»ÁúÀº ¿ªµ¿ÀûÀÌ¸ç »ý¹° ÀÇÇÐÀÇ ²÷ÀÓ¾ø´Â Áøº¸¿Í ÁøÈ­ÇÏ´Â ¼¼°è °Ç°­ ¼ö¿ä¿¡ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. Áö¼Ó°¡´ÉÇÑ »ç¾÷ ¼ºÀåÀ» À§ÇØ ÀÌÇØ°ü°èÀÚµéÀº °­·ÂÇÑ ¿¬±¸°³¹ßÀ» ÃßÁøÇϰí, º¸´Ù È¿°úÀûÀÎ À¯Åë ä³ÎÀ» À§ÇÑ ÆÄÆ®³Ê½ÊÀ» Ű¿ì°í, º¯È­ÇÏ´Â »çȸÀÇ ¿ä±¸¿Í ±ÔÁ¦ »óȲ¿¡ ´ëÀÀÇϱâ À§ÇÑ ÀûÀÀ Àü·«À» ½ÃÇàÇØ¾ß ÇÕ´Ï´Ù. ¹é½ÅÀÇ °¡¿ë¼º°ú È¿À²¼º Çâ»ó¿¡ ÁÖ·ÂÇÏ°í ½Å¼ÓÇÑ ¹é½Å °³¹ß°ú À¯ÅëÀ» ÃËÁøÇÏ´Â ±â¼ú¿¡ ÅõÀÚÇÔÀ¸·Î½á ½ÃÀåÀº °úÁ¦¸¦ ±Øº¹ÇÏ°í ¼ºÀå ±âȸ¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023³â) 176¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø³â(2024³â) 191¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø³â(2030³â) 307¾ï 8,000¸¸ ´Þ·¯
CAGR(%) 8.28%

½ÃÀå ¿ªÇÐ : ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â ¼ºÀÎ¿ë ¹é½Å ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¼ºÀÎ¿ë ¹é½Å ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú Á¦Á¶ ºñ¿ë ¶Ç´Â ±¸¸Å Ãß¼¼¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇØ ´õ ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Porter's Five Forces : ¼ºÀÎ¿ë ¹é½Å ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ ¿öÅ©´Â ±â¾÷ÀÇ °æÀïÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» ¼³¸íÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» ÇØ°áÇϰí ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¼ºÀÎ¿ë ¹é½Å ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¼ºÀÎ ¹é½Å ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ ¼³¸íÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¼ºÀÎ ¹é½Å ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

¼ºÀÎ ¹é½Å ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ¼¼ºÐÈ­ ¹× ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í °ø±Þ¾÷ü´Â °æÀïÀÌ Ä¡¿­ÇØÁö¸é¼­ ÀÚ½ÅÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ¼ºÀÎ ¹é½Å ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¼ºÀÎ¿ë ¹é½Å ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : ¼ºÀÎ ¹é½Å ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æ ±×¸®±â

¼ºÀÎ¿ë ¹é½Å ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ´É·Â ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ¸¶·ÃÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æ¿¡ ´ëÇØ »ó¼¼È÷ °ËÅäÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÎ¹®¿¡¼­ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» ¼³¸íÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ°í ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» Á¶»çÇß½À´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡µµ ´äº¯Çϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð ¹× ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ ¹× ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À² ¹× °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ÀÇ·á ÀÎÇÁ¶óÀÇ È®´ë¿Í ¹é½Å Á¢Á¾ ¼­ºñ½º¿¡ ¾×¼¼½º
      • °³ÀÎÀ̳ª Áö¿ª»çȸ¿¡¼­ÀÇ ¿¹¹æÀÇ·áÀÇ Á߿伺 Áõ°¡
      • ¹é½ÅÀ¸·Î ¿¹¹æ °¡´ÉÇÑ »õ·Î¿î ÁúȯÀ̳ª º¯ÀÌüÀÇ ÃâÇö
    • ¾ïÁ¦¿äÀÎ
      • ¹é½ÅÀÇ °³¹ß°ú À¯Åë¿¡ ¼ö¹ÝÇÏ´Â °íºñ¿ëÀÌ ½ÃÀå¿¡ ´ëÇÑ ¾×¼¼½º Á¦ÇÑ
    • ±âȸ
      • ¿©Çà¾÷°èÀÇ ÀÌÇØ°ü°èÀÚ¿Í Çù·ÂÇÏ¿© ¿©Çà ¹é½ÅÀ» ÃßÁøÇÏ¿© ¿©ÇàÀÚÀÇ °Ç°­ È®º¸
      • ¹é½Å Á¢Á¾·üÀ» ³ôÀ̱â À§ÇØ ³ëÀÎÃþÀ» ´ë»óÀ¸·Î ÇÑ Á¾ÇÕÀûÀÎ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥
    • °úÁ¦
      • ¾ö°ÝÇÑ Á¤ºÎ ±ÔÁ¦¿Í Àå±â°£ÀÇ ½ÂÀÎ ÇÁ·Î¼¼½º°¡ ¹é½Å ½ÃÀåÀÇ È®´ë ¹æÇØ
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTLE ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¼ºÀÎ¿ë ¹é½Å ½ÃÀå : ¹é½Å À¯Çüº°

  • ¼­¹®
  • ºÒȰȭ ¹é½Å
    • ¹ÙÀÌ·¯½º ¹é½ÅÀÇ ºÐÇÒ
    • ¸ðµç ¹ÙÀÌ·¯½º ¹é½Å
  • »ý ¾àµ¶È­ ¹é½Å
  • ¾Æ´ÜÀ§ ¹é½Å
    • ´Ù´ç·ù ¹é½Å
    • ´Ü¹éÁú ¾Æ´ÜÀ§ ¹é½Å
  • Åå¼ÒÀÌµå ¹é½Å

Á¦7Àå ¼ºÀÎ¿ë ¹é½Å ½ÃÀå : ÀûÀÀ Áúȯº°

  • ¼­¹®
  • BÇü °£¿°
  • ´ë»óÆ÷Áø
  • ÀÎÀ¯µÎÁ¾ ¹ÙÀÌ·¯½º(HPV)
  • ÀÎÇ÷翣ÀÚ
  • Æó·Å±¸±Õ °¨¿°Áõ

Á¦8Àå ¼ºÀÎ¿ë ¹é½Å ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¼­¹®
  • Ŭ¸®´Ð
  • ÀçÅÃÄ¡·á
  • º´¿ø
  • ¹é½Å Á¢Á¾ ¼¾ÅÍ

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ¼ºÀÎ¿ë ¹é½Å ½ÃÀå

  • ¼­¹®
  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ¼ºÀÎ¿ë ¹é½Å ½ÃÀå

  • ¼­¹®
  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¼ºÀÎ¿ë ¹é½Å ½ÃÀå

  • ¼­¹®
  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼® ¹× Á¦¾È
AJY 24.10.31

The Adult Vaccines Market was valued at USD 17.63 billion in 2023, expected to reach USD 19.11 billion in 2024, and is projected to grow at a CAGR of 8.28%, to USD 30.78 billion by 2030.

The adult vaccines market encompasses the development, production, and application of vaccines aimed at preventing infectious diseases in adults. This market addresses the increasing necessity for vaccination due to factors such as the aging global population, rising awareness about preventable diseases, and governmental immunization initiatives. The application scope includes vaccines against influenza, meningitis, HPV, and hepatitis, with end-uses ranging from individual health maintenance to public health programs. Key factors influencing growth include heightened governmental focus on healthcare policies, advances in vaccine technology, and the public's growing awareness of disease prevention. Opportunities abound in emerging markets with low vaccination coverage, where increasing healthcare access can drive growth. Industry players should focus on collaboration with healthcare providers and public health organizations to expand outreach and education. However, challenges such as vaccine hesitancy, regulatory hurdles, and distribution logistics can limit market expansion. Furthermore, high R&D costs and time-consuming approval processes pose significant challenges. To overcome these, investment in innovative delivery technologies, such as needle-free systems, and research into combination vaccines can offer potential growth avenues. Additionally, personalized vaccines that cater to individual immune system variations could revolutionize the market. The nature of the adult vaccine market is dynamic, driven by constant advancements in biomedical science and evolving global health demands. For sustainable business growth, stakeholders should engage in robust R&D, foster partnerships for more effective distribution channels, and implement adaptive strategies to address fluctuating societal needs and regulatory landscapes. By focusing on improving vaccine accessibility and efficiency, and investing in technologies that facilitate rapid vaccine development and distribution, the market can navigate its challenges and harness opportunities for growth.

KEY MARKET STATISTICS
Base Year [2023] USD 17.63 billion
Estimated Year [2024] USD 19.11 billion
Forecast Year [2030] USD 30.78 billion
CAGR (%) 8.28%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Adult Vaccines Market

The Adult Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expansion of healthcare infrastructure and access to vaccination services
    • Growing emphasis on preventive healthcare among individuals and communities
    • Emergence of new vaccine-preventable diseases and variants
  • Market Restraints
    • High costs associated with vaccine development and distribution limit market reach
  • Market Opportunities
    • Collaborations with travel industry stakeholders to promote travel vaccines and ensure traveler health
    • Comprehensive immunization programs targeting the aging population to increase vaccine uptake
  • Market Challenges
    • Stringent government regulations and lengthy approval processes hinder vaccine market expansion

Porter's Five Forces: A Strategic Tool for Navigating the Adult Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Adult Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Adult Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Adult Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Adult Vaccines Market

A detailed market share analysis in the Adult Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Adult Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Adult Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Adult Vaccines Market

A strategic analysis of the Adult Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Adult Vaccines Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca, Bharat Biotech, BioNTech, CSL Limited, CureVac, Dynavax Technologies, Emergent BioSolutions, GlaxoSmithKline, Inovio Pharmaceuticals, Johnson & Johnson, Merck & Co., Moderna, Novavax, Pfizer, Sanofi, Seqirus, Serum Institute of India, Sinovac Biotech, Valneva SE, and Vaxart.

Market Segmentation & Coverage

This research report categorizes the Adult Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Vaccine Type, market is studied across Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, and Toxoid Vaccines. The Inactivated Vaccines is further studied across Split Virus Vaccines and Whole Virus Vaccines. The Subunit Vaccines is further studied across Polysaccharide Vaccines and Protein Subunit Vaccines.
  • Based on Disease Indication, market is studied across Hepatitis B, Herpes Zoster, Human Papillomavirus (HPV), Influenza, and Pneumococcal Disease.
  • Based on End User, market is studied across Clinics, Homecare Settings, Hospitals, and Vaccination Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expansion of healthcare infrastructure and access to vaccination services
      • 5.1.1.2. Growing emphasis on preventive healthcare among individuals and communities
      • 5.1.1.3. Emergence of new vaccine-preventable diseases and variants
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with vaccine development and distribution limit market reach
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborations with travel industry stakeholders to promote travel vaccines and ensure traveler health
      • 5.1.3.2. Comprehensive immunization programs targeting the aging population to increase vaccine uptake
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations and lengthy approval processes hinder vaccine market expansion
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Adult Vaccines Market, by Vaccine Type

  • 6.1. Introduction
  • 6.2. Inactivated Vaccines
    • 6.2.1. Split Virus Vaccines
    • 6.2.2. Whole Virus Vaccines
  • 6.3. Live Attenuated Vaccines
  • 6.4. Subunit Vaccines
    • 6.4.1. Polysaccharide Vaccines
    • 6.4.2. Protein Subunit Vaccines
  • 6.5. Toxoid Vaccines

7. Adult Vaccines Market, by Disease Indication

  • 7.1. Introduction
  • 7.2. Hepatitis B
  • 7.3. Herpes Zoster
  • 7.4. Human Papillomavirus (HPV)
  • 7.5. Influenza
  • 7.6. Pneumococcal Disease

8. Adult Vaccines Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Homecare Settings
  • 8.4. Hospitals
  • 8.5. Vaccination Centers

9. Americas Adult Vaccines Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Adult Vaccines Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Adult Vaccines Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca
  • 2. Bharat Biotech
  • 3. BioNTech
  • 4. CSL Limited
  • 5. CureVac
  • 6. Dynavax Technologies
  • 7. Emergent BioSolutions
  • 8. GlaxoSmithKline
  • 9. Inovio Pharmaceuticals
  • 10. Johnson & Johnson
  • 11. Merck & Co.
  • 12. Moderna
  • 13. Novavax
  • 14. Pfizer
  • 15. Sanofi
  • 16. Seqirus
  • 17. Serum Institute of India
  • 18. Sinovac Biotech
  • 19. Valneva SE
  • 20. Vaxart
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦